

Solos Endoscopy, Inc.
Information Statement
April 10, 2006

Item (i): The exact name of the issuer and its predecessor (if any).

Solos Endoscopy, Inc.

Previous names;

ViaDux Health, Inc.
Prime Capital Resources
Mobilevest, Inc.

Item (ii): The address of its principal executive offices.

65 Sprague St., West B
Boston, MA 02136

Item (iii): The state and date of incorporation, if it is a corporation.

Nevada, February 3, 2005

Item (iv): The exact title and class of each class of securities outstanding.

Common Stock

Item (v): The par or stated value of the security.

Preferred Stock par value, \$.01
Common Stock par value, \$.001

Item (vi): The number of shares or total amount of the securities outstanding for each class of securities outstanding and a list of securities offerings and shares issued for services in the past two years.

Preferred Stock: There are no shares issued or outstanding

	FYE	FQE	Current Date
Common Stock -Period	<u>12/31/05</u>	<u>3/31/06</u>	<u>4/7/06</u>
Shares authorized	70.0 mil	250.0 mil	250.0 mil
Shares outstanding	16.1 mil	30.6 mil	69.6 mil
Public float	3.6 mil	3.6 mil	8.1 mil
Number of shareholders	83	84	90

Common shares issued pursuant to Regulation D, Rule 504:

September, 2005, 2,842,500 shares
Feb/Mar, 2006, 4,540,000 shares

Common restricted shares issued for services: 31,605,056 shares.

Item (vii): The name and address of the transfer agent.

Florida Atlantic Stock Transfer
7130 Nob Hill Rd.
Tamarac, FL 33321

Item (viii): The nature of the issuer's business.

A. Business Development.

1. *Form of Organization.*

Corporation

2. *Year Issuer was organized.*

Solos Endoscopy, Inc. was incorporated in 2005,

3. *Fiscal Year End Date:*

December 31.

4. *Whether the issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding*

No

5. *Any Material reclassification, merger, consolidation or purchase or sale.*

Solos Endoscopy was re-domiciled from Florida to Nevada 2005. It was then known as Prime Capital Resources, Inc. When re-domiciled to Nevada, the name was changed to Viadux Health, Inc.

Recently, Viadux Health, Inc. acquired the business, assets and operations from Woodbine Optical Corp. This operating business is known as Solos Endoscopy. Viadux Health, Inc. had its name changed to Solos Endoscopy, Inc. Mr. Robert Segersten, principal of Woodbine Optical Corp. became the principal shareholder of Solos Endoscopy, Inc.

6. *Has the Company had any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments?*

None

7. *Has the Issuer undergone any change of control?*

Yes, Bob Segersten became the controlling shareholder of Solos Endoscopy, Inc. (fka Viadux Health, Inc.; fka Prime Capital Resources, Inc.).

8. *Has there been an increase in Ten (10%) Percent or more of the same class of outstanding equity securities?*

Yes, the common stock was increased for shares issued in the acquisition of the assets from Woodbine Optical Corp.

9. *Describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization.*

****** The Company had a 1/5,000 reverse split of it's common stock September, 2005.

****** Shares were issued to Robert Segersten for the acquisitions of the assets of the Solos Endoscopy owned by Woodbine Optical Corp. Mr. Segersten is the principal and controlling shareholder of Woodbine Optical Corp.

10. *Whether the issuer has been delisted by any securities exchange or NASDAQ or deletion from the OTC Bulletin Board.*

None

11. *Whether there are any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations. Whether there are any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.*

B. Business of the Issuer. Provide a description of the Issuer's business so a potential investor can clearly understand it.

1. *Issuer's Primary and Secondary SIC Codes.*

Primary SIC Code is..... 3841. Cannot locate a secondary SIC Code.

2. *Whether the Issuer has never conducted operations, is in the development stage or is currently conducting operations.*

The issuer is currently conducting operations

3. *State the names of any parent, subsidiary, or affiliate of the issuer, and describe its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure document.*

None

4. *The effect of existing or probable governmental regulations on the business.*

The Company must comply with FDA and European CE Mark requirements for its products in order to sales its products in the respective markets. The Company has complied with the FDA requirements on its products. The Company may have to file CE Marks for several of its products in order to enter international markets.

5. *An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers.*

Nil

6. *The costs and effects of compliance with environmental laws (federal, state and local).*

Not Applicable

7. *Number of total employees and number of full-time employees*

The total number of employees and full time employees is Five (5).

C. Investment Policies. For any investments that the issuer has, provide clear descriptions of the investments, any restrictions or impairments the investments may have and the policies used to value and/or depreciate such assets from a financial and tax perspective. State whether there are any limitations of the percentage of assets which may be invested in any one investment, or type of instrument, and indicate whether such policy may be changed without a vote of security holders. State whether the issuer's policy is to acquire assets primarily for possible capital gain or primarily for income. If the issuer owns any real estate, interests in real estate, mortgages or securities related to or backed by real estate, describe the issuer's policies with respect to each of the following types of investments.

None

. *Investments in real estate or interests in real estate*. Indicate the types of real estate in which the issuer may invest, and describe the method (or proposed method) of operating and financing these properties. Indicate any limitations on the number or amount of mortgages that may be placed on any one piece of property.

None.

2. *Investments in real estate mortgages*. Indicate the types of mortgages and the types of properties subject to mortgages in which the issuer plans to invest. Describe each type of mortgage activity in which the issuer intends to engage, such as originating, servicing and warehousing, and the portfolio turnover rate.

Not Applicable

3. *Securities of or interests in persons primarily engaged in real estate activities*. Indicate the types of securities in which the issuer may invest, and indicate the primary activities of persons in which the issuer may invest and the investment policies of such persons.

Not Applicable

Item (ix): The nature of products or services offered.

1. Principal products or services, and their markets.
Specialty medical instrumentation for use in minimally invasive procedures. Includes, video cameras, instruments, optical couplers, and digital recording units. The primary markets are General, ENT and Breast surgery.
2. Distribution methods of the products or services.
The company utilizes specialty medical distribution, independent sales representatives, and direct sales in both the domestic and international markets.
3. Status of any publicly announced new product or service.
NA

4. Competitive business conditions, the issuer's competitive position in the industry, and methods of competition.
The company conducts business in the highly competitive healthcare industry. It has less than a 1% market share and is focused on niche markets.
5. Sources and availability of raw materials and the names of principal suppliers.
The company obtains its raw materials from both local and international suppliers. Its main supplier of goods is Tekno Medical.
6. Dependence on one or a few major customers
The company has over 200 reoccurring customers.
7. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration.
The company holds the trademark for "Solos".
8. The need for any government approval of principal products or services. Discuss the status of any requested government approvals.
The company is required to obtain Federal Drug Administration approval for its products and services. The company has all the proper approvals and is in good standing with the FDA.

Item (x): Describe the nature and extent of the issuer's facilities.

If the issuer owns any property or properties, for which the book value amounts to 10 percent or more of the total assets of the issuer and its consolidated subsidiaries for the last fiscal year furnish the following information for each such property (otherwise disclosure of the below items 1-7 does not need to be included):

1. Describe the general character and locations of all materially important properties held or intended to be acquired by or leased to the issuer and describe the present or proposed use of such properties and their suitability and adequacy for such use. Properties not yet acquired should be identified as such.

The company does not own or intend to acquire any properties.

2. State the nature of the issuer's title to, or other interest in, such properties and the nature and amount of all material mortgages, liens or encumbrances against such properties. Disclose the current principal amount of each material encumbrance, interest and amortization provisions, prepayment provisions, maturity date and the balance due at maturity assuming no prepayments.

Not Applicable

3. Outline briefly the terms of any lease or any of such properties or any option or contract to purchase or sell any of such properties.

The company currently leases an 8,000sqft facility in Boston. The lease is a month to month with no long term obligations.

Item (xi): The name of the chief executive officer, members of the board of directors, as well as counsel, accountant and public relations consultant.

- A. Officers, Directors and Advisors. The full names, business addresses, employment histories (which should list all previous employers for the past 10 years, positions held, responsibilities and employment dates), board

memberships, other affiliations, and number of securities (and of which class) beneficially owned by each such person, which information must be no older than the date of this information statement, for the issuer's:

Robert Segersten, President . Has been affiliated with the company for over 15 years and has held the current title for the last 6 years. He is also a member of the board of directors. Mr. Segersten is the major shareholder of the company with a greater than 50% position.

Dom L. Gatto: Director

His professional experience includes many different areas in the medical industry. He has been involved in areas ranging from product management to executive management. He acquired his knowledge of the medical device industry over the last fifteen years from a hands on perspective. He started out as a product manager for one of the world's largest producers of medical textile products - CoNco Medical Corporation. Upon departing this large multi-national medical concern, he assumed the position "jack of all trades" in guiding a small, developing medical device company (Merocel Corporation) into becoming a world leader in its field of synthetic biocompatible polymers for use in microsurgical. After enjoying considerable success as the head of marketing and product development, his efforts turned to business development. He conducted a feasibility study to determine the viability of a new business division for minimally invasive medical instruments. When he found that such a venture was worthwhile and could be developed, FessCo, Inc. was formed to design, develop, manufacture, and market minimally invasive ENT products. FessCo, a Delaware Corporation wholly owned by Warburg-Pincus, was financially successful within in its first 9 months of sales, reaching over \$1.4 million in revenues. He had successfully developed and launched a line of innovative minimally invasive handheld cutting instruments and a self-irrigating powered tissue removal system, the first of its kind, for the ENT market. Within its third year of operation, FessCo, along with Merocel Corporation, was folded into Xomed Surgical Products and the operations moved to Jacksonville, Florida. His proven track record allowed him to obtain the necessary support to form a start-up entity, MedTREK Corporation, to design, develop, and market minimally invasive ENT products. In 2000, after establishing the product line and worldwide distribution rights for MedTREK's products, he joined the breast cancer start-up company Acueity, Inc. as Senior Vice President of Operations. He skillfully guided Acueity's product development, sales, marketing and production. Acueity has been featured in Time magazine as one of the top five medical technologies for the breast cancer detection and treatment. Mr. Gatto holds a BS degree in Marketing from Quinnipiac University.

Jim Holmes: Director

EXPERIENCE

Chief Executive Officer of Lifeline Biotechnologies, a medical device company that has developed processes for the early detection of breast and ovarian cancers. The company is presently in clinical trials. Lifeline is a public company with over 9,000 shareholders.

Chief Executive Officer of Virtual Apothecary, a distributor of nutraceutical products through physicians; President of CCMCo., a business development, merger and acquisition and investment banking consulting company. Vice President of Nature's Creations Corp., a nutraceutical company; Director, Trendsetter Industries, Inc.

Formerly president, treasurer, chief financial officer, or controller/assistant controller of various industrial companies, private and public. This includes BioRad Labs (American Stock Exchange), Harvest Industries (OTC). Vice President and General Manager of North Coast Investments. Audit staff PricewaterhouseCoopers, international accounting and auditing firm.

PROFESSIONAL Certified Public Accountant

EDUCATION

Advanced Management College, Stanford University.

Graduate studies (MBA, Accounting and CPA Review) Golden Gate University.

Bachelor of Science, San Jose State University, business and accounting.

Numerous Venture Capital Seminars; Continuing Education (CPA).

Securities Institute seminars; American Marketing Association.

Legal:

Norman C. Sabbey
Lyne, Woodworth & Everts
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210

Public Relations:

Management Solutions International
280 Wekiva Springs Road Ste. 205
Longwood, FL 32779
Telephone: (407) 884-0444
Fax: (407) 884-0125

The principal occupation and business experience during the last several years is listed below for each of the present executive officers and directors.

Robert Segersten: He founded Woodbine Optical Corporation in 1991 in order to produce OEM video cameras for the medical marketplace. The company quickly added light sources, video couplers and relay lens to its product offering. Woodbine procured large OEM contracts from companies like Bircher Medical, Olympus, and ConMed. His relationship with Bircher Medical allowed Woodbine the opportunity to acquire the Solos Endoscopy Video division of Bircher. He successfully merged Solos into Woodbine and renamed the company – Solos Endoscopy capitalizing on the strong brand recognition of Solos. He grew the company to approximately \$3 million in sales, at which time he was approached by EndoImage and sold Solos in 1994. He stayed on as President until 1996. He remained an advisor to the company until he reacquired ownership in 2000. He is a graduate of Bates College and received his law degree from Boston University.

8. Accountant or Auditor - the information should clearly describe if an outside accountant provides audit or review services, state the work done by the outside accountant, describe the responsibilities of the accountant

The information should include the accountant's phone number and email address and a description of the accountant's licensing and qualifications to perform such duties on behalf of the issuer;

Fred Schiemann, CPA assisted in the preparation of the unaudited and preliminary financial statements dated at the acquisition March 22, 2005.

Mr. Schiemann's phone number is 775-324-2012 Ext 11; Email: Fschiemann@yahoo.com

9. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure documentation – the information should include the advisor(s)' telephone number and email address.

Dom Gatto: Currently an advisor to the company has assisted with this information.
(Tel# (203) 483-1257 or domgatto@comcast.net)

Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses). NO

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities. NO

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated. NO

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.
NO

C. Beneficial Owners. To the extent not otherwise disclosed in response to the foregoing, provide a list of the name, address and shareholdings all persons holding more than five percent (5%) of any class of the issuer's equity securities. To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the disclosure requested in this item as to person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Robert Segersten 65 Sprague St., West B Boston, MA 02136	32,861,966 common shares (50.9%)
--	----------------------------------

Dom Gatto AMG Development, LLC 1698 Post Road East, Ste 3E Westport, CT 06880	9,004,500 common shares (14.0%)
--	---------------------------------

Jim Holmes Carson Capital Management 1325 Airmotive Way, Ste 175 Reno, NV 89502	10,605,501 common shares (16.4%)
--	----------------------------------

Lifeline Biotechnologies, Inc.
1325 Airmotive Way, Ste 175
Reno, NV 89502

8,403,006 common shares (13.0%)

D. Disclosure of Certain Relationships. Describe any relationships existing among and between the issuer's officers, directors and shareholders. To the extent not otherwise disclosed, describe all relationships and affiliations among and between the shareholders and the issuer, its predecessors, its present and prior officers and directors and other shareholders.

Jim Holmes is CEO and a principal shareholder of Lifeline Biotechnologies, Inc.

Item (xii): Adequate disclosure of the issuer's (or its predecessor's) current financial position, which should include the most recent fiscal year and any interim quarters.

Submitted separately

Item (xiii): Similar financial information for such part of the 2 preceding fiscal years as the issuer or its predecessor has been in existence.

Submitted separately

Item (xiv): Whether any quotation is being submitted or published directly or indirectly on behalf of the issuer, or any director, officer, affiliate, or any person, directly or indirectly the beneficial owner of more than 10 percent of the outstanding units or shares of any equity security of the issuer, or at the request of any promoter for the issuer, and, if so, the name of such person, and the basis for any exemption under the federal securities laws for any sales of such securities on behalf of such person. A person is presumed to be an affiliate if they own more than 10% of the stock, but may be an affiliate even if they own less stock if the facts and circumstances indicate that they are participating with the issuer in a distribution of securities with a view to raising capital for the issuer.

No.

CERTIFICATION:

I, Bob Segersten, hereby certify that I have reviewed the Information and Disclosure Statement and I have full authority to sign on behalf of the Company and do hereby certify that the information contained herein is complete and presented fairly in all material respects.

Dated this 10 day of April, 2006.

Certified By: /s/ Bob Segersten
Bob Segersten, President